Posted on 29/04/2010 in Pharmaceutical Company Product News Ipsen and Roche have highlighted new results from a phase III clinical trial which support the efficacy of their diabetes trial taspoglutide.
The drug, which is being developed by Roche based on Ipsen's research, was trialled in a 24-week study involving 326 patients, in order to establish its effectiveness as an add-on for metformin and pioglitazone.
It was found that those using the treatment, which is the first once-weekly glucagon-like peptide-1 analogue drug based on a human sequence, demonstrated superior levels of HbA1c change compared to those in the placebo control group.
The drug was also generally well-tolerated by patients, with nausea and vomiting ranking as the most commonly-reported adverse events.
Ipsen stated that this data will now be presented at international scientific meetings in the near future, while two further phase III trials of taspoglutide were also confirmed as being ongoing.
Last month, Ipsen agreed a new collaboration with Dicerna Pharmaceuticals, which will see the companies research new endocrinology and oncology treatments based on Dicer Substrate siRNA and peptide technologies.Other news stories from 29/04/2010
Read more in the Zenopa News Archive
How this news is generated
|
